Jeffrey D Bray
Overview
Explore the profile of Jeffrey D Bray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen J, Xu L, Fang H, Richard A, Bray J, Judson R, et al.
Toxicol Sci
. 2013 Jul;
135(2):277-91.
PMID: 23897986
Endocrine-active chemicals can potentially have adverse effects on both humans and wildlife. They can interfere with the body's endocrine system through direct or indirect interactions with many protein targets. Estrogen...
2.
Herndon T, Deisseroth A, Kaminskas E, Kane R, Koti K, Rothmann M, et al.
Clin Cancer Res
. 2013 Jun;
19(17):4559-63.
PMID: 23775332
The U.S. Food and Drug Administration (FDA) review leading to accelerated approval of carfilzomib is described. A single-arm trial enrolled 266 patients with multiple myeloma refractory to the most recent...
3.
Monsivais D, Bray J, Su E, Pavone M, Dyson M, Navarro A, et al.
Fertil Steril
. 2012 Apr;
98(1):117-25.
PMID: 22521153
Objective: To define altered gene expression networks in endometriosis. Design: Experiments using endometriotic tissues and primary cells. Setting: Division of Reproductive Biology Research, Northwestern University. Patient(s): Premenopausal women. Intervention(s): Matched...
4.
Kallander L, Washburn D, Hoang T, Frazee J, Stoy P, Johnson L, et al.
Bioorg Med Chem Lett
. 2009 Nov;
20(1):371-4.
PMID: 19926282
The previously reported pyrrolidine class of progesterone receptor partial agonists demonstrated excellent potency but suffered from serious liabilities including hERG blockade and high volume of distribution in the rat. The...
5.
Glace L, Grygielko E, Boyle R, Wang Q, Laping N, Sulpizio A, et al.
Steroids
. 2009 Aug;
74(13-14):1015-24.
PMID: 19665469
Endometriosis, defined as the presence of endometrial glands and stroma at extra-uterine sites, is a gynecological condition that affects women of reproductive age. Consistent with its uterine origins, endometriotic lesions...
6.
Wang Y, Duraiswami C, Madauss K, Tran T, Williams S, Deng S, et al.
Bioorg Med Chem Lett
. 2009 Aug;
19(17):4916-9.
PMID: 19664922
High throughput screening of the corporate compound collection led to the identification of a novel series of 2-amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective PR agonists. Initial SAR exploration leading to potent and...
7.
Washburn D, Hoang T, Frazee J, Johnson L, Hammond M, Manns S, et al.
Bioorg Med Chem Lett
. 2009 Jul;
19(16):4664-8.
PMID: 19616429
We have designed and synthesized a novel series of pyrrolidinones as progesterone receptor partial agonists. Compounds from this series had improved AR selectivity, rat pharmacokinetic properties, and in vivo potency...
8.
Thompson S, Washburn D, Frazee J, Madauss K, Hoang T, Lapinski L, et al.
Bioorg Med Chem Lett
. 2009 Jul;
19(16):4777-80.
PMID: 19595590
Using the X-ray crystal structure of an amide-based progesterone receptor (PR) partial agonist bound to the PR ligand binding domain, a novel PR partial agonist class containing a pyrrolidine ring...
9.
Synthesis and SAR of amino acid-derived heterocyclic progesterone receptor full and partial agonists
Hammond M, Patterson J, Manns S, Hoang T, Washburn D, Trizna W, et al.
Bioorg Med Chem Lett
. 2009 Apr;
19(10):2637-41.
PMID: 19376703
Two classes of amino acid-derived heterocyclic progesterone receptor ligands were developed to address the metabolic issues posed by the dimethyl amide functionality of the lead compound (1). The tetrazole-derived ligands...
10.
Sherk A, Frigo D, Schnackenberg C, Bray J, Laping N, Trizna W, et al.
Cancer Res
. 2008 Sep;
68(18):7475-83.
PMID: 18794135
Androgens, through their actions on the androgen receptor (AR), are required for the development of the prostate and contribute to the pathologic growth dysregulation observed in prostate cancers. Consequently, androgen...